CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 32 enrolled
Drug / intervention
Tranexamic Aciddrug
Likely dose
Tranexamic Acid 1300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02618382
NCT02618382Phase 4Completed

A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population

St. Joseph's Hospital and Medical Center, Phoenix·interventional·Posted Dec 1, 2015·Updated Nov 11, 2021

In Brief

A Phase 4 clinical trial evaluating Tranexamic Acid for Subdural Hematoma. Completed, enrolled 32 participants across 1 site.

Detailed Summary

This is a single center single arm study of 50 patients to 1) determine the safety of tranexamic acid in the chronic subdural hematoma population following surgical drainage of chronic subdural hematomas and 2) determine if the use of oral tranexamic acid reduces the rate of ipsilateral recurrence following drainage of chronic subdural hematomas. This will be compared to historical controls. This study intends to be a prerequisite to a large nationally funded randomized control trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 1, 2015
Enrollment StartNov 1, 2015
Primary CompletionAug 1, 2017
Study CompletionJun 12, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.6 years ago

Interventions

Tranexamic Aciddrug

1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first